Satraplatin's Stumble: Is Accelerated Approval Under Threat?
This article was originally published in RPM Report
GPC Biotech was dealt a nasty blow when an FDA advisory committee recommended against approving satraplatin for prostate cancer until the company submits more data. The outcome left some analysts questioning the future of an important approval pathway for small biotech companies.
You may also be interested in...
Spec pharma has created significant value in the US, but not, so far, in Europe. Still, Europe's spec pharma hopefuls aren't giving up, and they're trying out variations on the theme--some starting with infrastructure, others with products.
GlaxoSmithKline's diabetes drug Avandia survived a perilous FDA advisory committee review. The real question is whether the industry can survive the damage to FDA's credibility.
Dendreon's therapeutic cancer vaccine Provenge is the first of its kind to make it to an FDA advisory committee. The committee gave the novel agent a thumbs up. But FDA may disagree and turn away the prostate cancer vaccine until there is more conclusive data of its safety and effectiveness. How much does Dendreon stand to lose?